Transfusion medicine for the pediatrician

https://doi.org/10.1016/S0031-3955(02)00090-1Get rights and content

Section snippets

Screening for infectious disease

Currently, all blood donations are screened for HIV antigen, antibodies to HIV-1 and HIV-2, human T lymphotrophic virus (HTLV I-II), hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBC), hepatitis C (HCV), and syphilis. Nucleic acid testing (NAT) [5], used under an investigative new drug license from the US Food and Drug Administration (FDA), uses a transcription-mediated amplification [6] to test for HIV and hepatitis C but not hepatitis B. There are algorithms to define

Viral pathogens/NAT testing

Once an individual has become infected with a viral pathogen, there is a window of time (Fig. 2) during which the viral load is too low, or is intermittently too low, to be detected by pooled sample NAT. Recipients of donated blood products are at highest risk for infection during this window phase. Because NAT testing is so sensitive and there are so few instances of virally infected products, only mathematical models based on research data can predict the risk of infection from a single

Bacterial contamination of blood products

Bacterial sepsis from contaminated blood products is the second leading cause of transfusion-related death (Fig. 4) in the United States today, behind transfusion errors. Between 1990 and 1998, there were 277 reported transfusion-related deaths, 17% of which were due to bacterial contamination. The fact that patients receiving blood transfusions are likely to have complex medical conditions and are frequently immune suppressed contributes to the morbidity of transfusion-related sepsis. The

Emerging pathogens

With the advent of comprehensive donor screening, NAT testing, and perhaps universal leukoreduction, blood transfusion is safer than it was only a decade ago. Pathogens like HIV, HCV, and HBV are a persistent but vanishing risk of transfusion. Infections once considered low risk have become more significant (Table 2). For these low-risk pathogens there are no approved screening tests. The blood supply is protected by accurate history taking and deferral at the time of donation and in some cases

Transfusion-mediated immune modulation

The first well-documented immune effect of transfusion was reported in 1973 by Opeiz et al [57] and showed increased survival of renal allografts in patients who had received allogeneic blood transfusions before transplantation. Since this report, there have been numerous studies and reports of the immune effects of transfusion [58]. Microchimerism has been detected decades following transfusion of whole blood and other products containing viable leukocytes [59]. Transfusion-related graft

Transfusion-related acute lung injury

In August 2001, a letter circulated by the US Department of Health and Human Services warned about the possibility of transfusion-related acute lung injury (TRALI) in transfused patients [65]. There have been 45 reported fatalities since 1992. TRALI is thought to be responsible for 13% of all transfusion fatalities, making it the third leading cause of transfusion-related death. Most deaths have been associated with the administration of fresh frozen plasma, but TRALI has also been reported

Leukoreduction

Leukoreduction was first proposed as a goal for the blood industry in 1995 by the FDA. In January 2001, Guidance for Industry [70] was released, arguing in favor of universal leukocyte reduction. In addition, this document set forth industry standards for quality assurance, quality monitoring, registration, and production licensure. The FDA argument accepted most of the reasoning in favor of leukoreduction: transfusion-associated immunomodulation, bacterial overgrowth, viral reactivation,

Pathogen inactivation

Pathogen inactivation has been a goal of blood banking since the 1940s, when the pasteurization of albumin was used to prevent jaundice following its infusion. For stable products such as albumin, there have been advances since the 1980s, such as solvent/detergent processing to nanofiltration methods, in the processes used to create a safer product. This article does not explore the methods used for the purification of nonlabile blood products, because an excellent review of this topic has

Prolonging red blood cell storage

In 1961, Simon et al [76] demonstrated that adenine could be added to red blood cells to prolong their survival. In 1977, Zuck et al [77] demonstrated that this was a viable method of preservation, convincing the FDA to approve adenine for red blood cell storage. With the removal of plasma and the use of additive solutions (AS-1, AS-3, and CPDA-1, CPDA-2 or CPDA-3), the storage life of blood is currently 42 days. Even with these additive solutions, there continues to be a storage lesion

Summary

In the next decade, many of the methodologies and research reviewed in this article will become clinical practice, making the transfusion of blood products safer and more universally available than they are today. NAT will be standard and will surely be performed on each unit of product, PCR testing for pathogens will evolve, and the pathophysiology and immunology of transfusion-related events such as TRALI and immunomodulation will be elucidated. New methods of preservation and early detection

First page preview

First page preview
Click to open first page preview

References (83)

  • C.C Silliman

    Transfusion-related acute lung injury

    Transfus Med Rev

    (1999)
  • J Morgenthaler

    Securing viral safety for plasma derivatives

    Transfus Med Rev

    (2001)
  • J.A Grass et al.

    Prevention of transfusion-associated graft-versus-host disease by photochemical treatment

    Blood

    (1999)
  • Center for Biologics Evaluation and Research (CEBER). Current good manufacturing practices (21CFR 606): implementation...
  • P.P Ulrich et al.

    Enzymatic amplification of hepatitis B virus DNA in serum compared with infectivity testing in chimpanzees

    J Infect Dis

    (1989)
  • D.M Lubin

    Universal RBC's

    Transfusion

    (2000)
  • Pathogen inactivation of labile blood products

    Transfus Med

    (2001)
  • M.P Busch et al.

    Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases:

    Transfusion

    (2000)
  • S.L Stramer et al.

    NAT of the United States and Canadian blood supply

    Transfusion

    (2000)
  • M.P Busch

    Closing the windows on viral transmission by blood transfusion

  • B Jackson et al.

    Cost-effectiveness of nucleic acid testing for HIV and HCV in donated blood [abstract]

    Transfusion

    (2000)
  • R.Y Dodd

    Germs, gels, and genomes: a personal recollection of 30 years in blood safety testing

  • Stramer S.L. Reentry for donors deferred because of HIV or HVC NAT or serological test results. Presented for BPAC June...
  • G.B Schreiber et al.

    The risk of transfusion-transmitted viral infections

    N Engl J Med

    (1996)
  • S.H Kleinman et al.

    HBV: amplified and back in the spotlight

    Transfusion

    (2001)
  • M Yoshida et al.

    Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative roll of human T-cell leukemia virus in the disease

    Proc Natl Acad Sci U S A

    (1984)
  • A Gessain et al.

    Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I)

    Ann Intern Med

    (1992)
  • M Mochizuki et al.

    HTLV-I uveitis: a distinct clinical entity caused by HTLV-I

    Jpn J Cancer Res

    (1992)
  • M.P Busch et al.

    Absence of evidence of infection with divergent primate T-lymphotropic viruses in United States blood donors who have seroindeterminate HTLV test results

    Transfusion

    (2000)
  • E.L Murphy et al.

    Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors

    J Infect Dis

    (1997)
  • P Perez et al.

    Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study

    Transfusion

    (2001)
  • L.M Williamson et al.

    Serious hazards of transfusion (SHOT) initiative: analysis of the first two years

    BMJ

    (1999)
  • L Williamson et al.

    The serious hazards of transfusion (SHOT) initiative: the UK approach to haemovigilance

    Vox Sang

    (2000)
  • K.M Michell et al.

    Approaches to the detection of bacterial contamination in cellular blood products

    Transfus Med Rev

    (1999)
  • C.P McDonald et al.

    Evaluation of donor arm disinfection techniques

    Vox Sang

    (2001)
  • P.M Ness et al.

    Transient bacteremia after dental procedures and other minor manipulations

    Transfusion

    (1980)
  • F Holden et al.

    Coagulase-negative staphylococcal contamination of whole blood and its components: the effects of WBC reduction

    Transfusion

    (2000)
  • C.F Hogman et al.

    The role of white cells in the transmission of Yersinia enterocolitica in blood components

    Transfusion

    (1992)
  • P Ness et al.

    Single-donor platelets reduce the risk of septic platelet transfusion reactions

    Transfusion

    (2001)
  • J.F Marrow et al.

    Septic reactions to platelet transfusions

    JAMA

    (1991)
  • E.K Chiu et al.

    A prospective study of symptomatic bacteremia following platelet transfusion and of its management

    Transfusion

    (1994)
  • Cited by (8)

    • Systemic Disorders in Infants and Children

      2006, Smith's Anesthesia for Infants and Children
    • Systemic Disorders in Infants and Children

      2005, Smith's Anesthesia for Infants and Children, Seventh Edition
    • Transfusions in paediatrics

      2017, Salud Uninorte
    • Transfusion reaction

      2012, Fleisher and Ludwig's 5-Minute Pediatric Emergency Medicine Consult
    • Supportive Care of the Pediatric Hematopoietic Stem-Cell Transplant Patient

      2006, Pediatric Hematopoietic Stem Cell Transplantation
    View all citing articles on Scopus
    View full text